PREDICTORS OF INFLIXIMAB TROUGH CONCENTRATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS USING A REPEATED MEASURES DESIGN

AbstractBackground and Aims:Treating patients based on a treat-to-trough approach has been shown to be a cost-effective strategy for inflammatory bowel disease (IBD) patients who have become unresponsive to infliximab (IFX). However, the documented evidence for this is limited, and some controversy